Study Objectives: Yearly seasonal influenza pandemic has been an important public health issue around the world. There had been 2 major outbreaks in Taiwan in 2009 and 2016. More than 100 severe complicated influenza cases were reported to the Center of Disease Control, Taiwan. Mortality rate was about 30% among these patients. Early prediction of patients with potentially worse outcome is important in the emergency department. Sepsis-3 was the latest definition of sepsis published in 2017. qSOFA score had been developed as the initial evaluation tool of sepsis. In this study, we aimed to investigate the effectiveness of qSOFA score as a prognosis predictor of patients with influenza in the emergency department.
Methods: This is a single-centered, retrospective cohort study. All the data were retrieved from a hospital-based research database. Adult patients (age S 18 at admission) with a positive influenza rapid screening test or a positive Influenza virus polymerase chain reaction (PCR) from 2010 to 2016 were enrolled for data analysis. qSOFA score and systemic inflammatory response syndrome (SIRS) in the emergency department were both collected. Patients' data including basic characteristics, hospitalization status, and outcome were collected. The primary outcome is the performance of both scores in predicting in-hospital mortality.
Results: In the study period, 3,561 patient visits met the inclusion criteria. Mean patient's age was 48.1 AE 19.5 with nearly equal sex distribution (48.2 % male). 1,527 patients (42.9%) were admitted to the hospital. 286 patients (8%) were admitted to the intensive care unit (ICU). The overall in-hospital mortality was 2.7%. with an overall in-hospital mortality rate of 2.7% (95 patients). When qSOFA score is 0, 1, 2, and 3, the percentage of hospital admission was 34.3%. 66.7%, 80.4%, and 75%, respectively. Accordingly, the in-hospital mortality was 0.6%, 7.2%, 15.9%, and 25%, respectively. The odds ratios of in-hospital mortality were 7.72 (4.35-13.70, 95% confidence interval), 11.92 (5.74-24.77), and 22.46 (4.33-116.61 ) when qSOFA score was 1, 2, and 3, respectively (all p value < 0.001). The odds ratios of ICU admission were 7.21 (5. 35-9.73), 12.54 (8.04-19.56), and 38.7 (11.73-127.72 ) when qSOFA score was 1, 2, and 3, respectively (all p<0.001). The sensitivity and specificity of when aSOFA score S 2 was 24% and 96.2%, respectively. Area under depicted ROC curve was 0.864, which is significantly higher compared to SIRS criteria, which was 0.786 (p < 0.01).
Conclusions: Influenza infection was usually a self-limited disease with low inhospital mortality. Disease progression of severe complicated influenza might develop in a very short time interval. qSOFA score at presentation in the emergency department greater than 2 was a prognostic predictor for both ICU admission and in-hospital mortality but it should not be used to exclude further deterioration due to its poor sensitivity.
Impact of an Emergency Department Antimicrobial Stewardship Program on the Rate of Beta-Lactam Allergy Challenge
Eischens MR, Wolf LM, Dumkow LE, Anderson AM, Jameson AP, Brandt KL/Mercy Health Saint Mary's, Sparta, MI; Mercy Health Saint Mary's, Grand Rapids, MI Study Objectives: Penicillin allergies limit the use of first-line antimicrobials and are associated with poor patient outcomes and increased costs of care. Penicillin skin testing is a method for challenging penicillin allergies; however, this method may not be feasible in all settings as it is time and resource intensive. Data suggests that cephalosporins have a much lower rate of cross-reactivity to penicillins than previously believed and are generally considered safe in non-severe penicillin allergic patients. Emergency department (ED) pharmacists are well positioned to conduct antimicrobial stewardship interventions, including allergy clarifications and challenges. The primary outcome of this study was to compare the rate of beta-lactam allergy challenge in the ED over time, defined as receipt of either a penicillin or cephalosporin despite a documented beta-lactam allergy. Secondary outcomes compared the rate of patients receiving first-line treatment, defined as empiric therapy based on institutional guidelines, as well as allergy challenge rates in the ED when an ED pharmacist was present versus absent. Additionally, patient outcomes were compared when a betalactam allergy was challenged versus an alternative agent administered.
Methods: A retrospective cohort study was conducted at a 44-bed urban ED treating over 75,000 patients annually. The ED-antimicrobial stewardship program (EASP), established in October 2013, includes leadership of 2 ED pharmacists and 1 infectious diseases pharmacist. Three time periods were compared: pre-EASP (2010), early-EASP (2014), and established-EASP (2016). A subgroup analysis was conducted comparing the rate of beta-lactam allergy challenge when an ED pharmacist was present versus absent. Adult patients were eligible for inclusion if they were admitted to the hospital from the ED with a diagnosis of community-acquired pneumonia, community-acquired intra-abdominal infection, or UTI/pyelonephritis. Data collected included patient demographics, allergy characteristics, antibiotic therapy, allergy challenge and clinical outcomes. Statistical analysis was performed using SPSS and a pvalue less than 0.05 was considered statistically significant.
Results: A total of 250 patients were included for analysis (pre-EASP n ¼ 34, early-EASP n ¼ 103, established-EASP n ¼ 113). Baseline demographics were similar among groups. The majority of patients had a penicillin allergy (86.8%) compared to a cephalosporin allergy (19.6%); 7.2% of patients reported both. Allergies were classified as being non-severe in the majority of patients (72.4%). The rate of beta-lactam allergy challenge in the ED increased over time (pre-EASP 5.9%, early-EASP 56.3%, established-EASP 68.1%, p < 0.001). Rates of first-line treatment also increased from 2010 to 2014 and 2016 (2.9%, 46.6%, 55.8%, p < 0.001). Clinical outcomes were similar between groups, with only one patient developing a non-anaphylactic allergic reaction following a beta-lactam challenge. First-line treatment was 58.4% when an ED pharmacist was present versus 41.8% when absent (p ¼ 0.016).
Conclusions: Following the implementation of a pharmacist-driven EASP, significantly more patients with a beta-lactam allergy had their allergy challenged and received first-line treatment. Less than 1% of patients whose allergy was challenged developed an allergic response. Results of this study support EASPs to increase the use of first-line beta-lactam therapies.
